Stock Quotes in this Article: CBLI, CUR, CVM, INO, NVAX

DELAFIELD, Wis. (Stockpickr) -- The biotechnology sector is in focus the next two days on Wall Street as the BIO CEO & Investor Conference gets underway. This conference is in its sixteenth year, and it's the largest investor conference focused on established and emerging publicly traded and select private biotech companies. The event gives institutional investors, industry analysts and senior biotechnology executives a chance to openly discuss biotech firms' prospects and the ever-changing world of biotechnology.

>>5 Hated Earnings Stocks You Should Love

Traders, like myself, will be focusing on trading any momentum off the fast-moving small-cap biotechnology stocks that will be in play as the companies present at BIO CEO. I have been scanning the charts of many these names looking for some potential fast trades that could play out nicely over the next two days and potentially the next few months. I have found a number of bullish small-cap biotech stocks that will be presenting at the conference, so all we need now is for these stocks to get some volume and break out and we could easily bank some serious short- and mid-term profits.

The stocks I picked aren't just flagging decent setups into their presentations, but they also have longer-term bullish setups. These are names to keep on your trading radar even if we don't get any momentum into the conference or off their presentations. That being said, if the CEOs of these biotech stock say anything bullish that the market likes, then look out, because these stocks could make explosive moves.

>>5 Biotech Stocks Spiking on Unusual Volume

With that in mind, here's a look at five stocks that are scheduled to present at the conference on Tuesday that could make sharp spikes higher.

Neuralstem


One biotechnology player that's presenting at the conference on Tuesday at 3 p.m. is Neuralstem (CUR), which focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. This stock has been on fire over the last six months, with shares up huge by 117%.

If you take a look at the chart for Neuralstem, you'll notice that this stock has already found buyers on Monday, with shares up 7.5% as I type this. That's OK, because the big trade in shares of Neuralstem is going to come when this stock breaks out with volume to new 52-week highs. That trade is quickly approaching, since shares of CUR have been uptrending strong over the last six months, with shares moving higher from its low of $1.43 to its 52-week high at $3.75 a share. Shares of CUR are now trending within shouting distance of triggering a breakout trade to new 52-week highs.

>>5 Stocks Poised for Breakouts

Traders should now look for long-biased trades in CUR if it manages to break out above some near-term overhead resistance levels at $3.64 a share to its 52-week high at $3.75 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 940,595 shares. If that breakout hits soon, then CUR will set up to enter new 52-week-high territory, which is bullish technical price action. This stock could easily spike 15% to 20% quick off that breakout, but some possible longer-term upside targets are $4.50 to $5 a share.

Traders can look to buy CUR off modest weakness to anticipate that breakout and simply use a stop that sits a comfortable percentage point from your entry. One can also buy CUR off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Cleveland BioLabs


A biotechnology player that presents on Tuesday at 11:30 a.m. is Cleveland BioLabs (CBLI), which engages in the research, development and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation and counteract the genotoxic effects of radio- and chemotherapies for oncology patients. This stock has been destroyed by the sellers so far in 2014, with shares off by 40%.

>>5 Rocket Stocks to Buy for a Market Bounce

If you take a look at the chart for Cleveland BioLabs, you'll notice that this stock recently gapped down sharply from over $1.10 to 63 cents per share with heavy downside volume. Following that gap, shares of CBLI have started to consolidate and form a double bottom chart pattern at 63 cents per share. This stock has now started to spike higher off that 63 cents per share low and it's quickly moving within range of triggering a major breakout trade above some key near-term overhead resistance levels.

Traders should now look for long-biased trades in CBLI if it manages to break out above some near-term overhead resistance levels at 71 to 75 cents per share and then once it takes out its gap-down-day high of 84 cents per share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 369,940 shares. If that breakout triggers soon, then CBLI will set up to re-fill some of its previous gap-down-day zone that started at $1.16 a share.

Traders can look to buy CBLI off any weakness to anticipate that breakout and simply use a stop that sits right below its double bottom support area at 63 cents per share. One could also buy CBLI off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

CEL-SCI

Another biotherapeutic player that's presenting on Tuesday at 3:00 p.m. is CEL-SCI (CVM), which is engaged in the research and development of drugs and vaccines. This stock is off to a monster start in 2014, with shares up a whopping 82%.

>>5 Big Trades to Take in February

If you take a look at the chart for CEL-SCI, you'll notice that this stock has been uptrending strong over the last month and change, with shares ripping higher from its low of 53 cents per share to its recent high of $1.17 a share. During that uptrend, shares of CVM have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CVM within range of triggering a major breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in CVM if it manages to break out above some near-term overhead resistance levels at $1.12 to $1.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.59 million shares. If that breakout triggers soon, then CVM will set up to re-test or possibly take out its next major overhead resistance levels at $1.40 to its 200-day moving average at $1.60 a share. Any high-volume move above those levels will then give CVM a chance to tag $2 a share.

Traders can look to buy CVM off any weakness to anticipate that breakout and simply use a stop that sits a comfortable percentage from your entry point. One can also buy CVM off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Novavax


Another clinical stage biopharmaceutical player that presents on Tuesday at 3 p.m. is Novavax (NVAX), which focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. This stock has been exploding to the upside over the last six months, with shares up huge by 141%.

>>5 Stocks Under $10 Set to Soar

If you look at the chart for Novavax, you'll notice that this stock has pulled back recently off its 52-week high of $6.50 to its low of $5.11 a share. Shares of NVAX have been able to hold above its 50-day moving average of $5.08 off that pullback. This stock is now starting to spike higher here and move within range of triggering a near-term breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in NVAX if it manages to break out above some near-term overhead resistance levels at $5.75 to $6.08 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 5.25 million shares. If that breakout hits soon, then NVAX will set up to re-test or possibly take out its 52-week high at $6.50 a share. Any high-volume move above that level will then give NVAX a chance to tag $7 to $7.50 a share.

Traders can look to buy NVAX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $5.08 a share. One can also buy NVAX off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Inovio Pharmaceuticals


My final biotechnology player that presents on Tuesday at 10:30 a.m. is Inovio Pharmaceuticals (INO), which engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. This stock has been in play with the bulls over the last six months, with shares up sharply by 40%.

If you look at the chart for Inovio Pharmaceutical, you'll notice that this stock is ripping higher here and breaking out above some near-term overhead resistance levels at $2.69 to $2.74 a share with high volume. The upside volume so far for INO has already surpassed its three-month average action of 4.27 million shares. This spike is quickly pushing shares of INO within range of triggering another big breakout trade.

Traders should now look for long-biased trades in INO if it manages to break out above some near-term overhead resistance levels at $2.97 a share to its 52-week high at $3 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 4.27 million shares. If that breakout triggers soon, then INO will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $4 to $4.50 a share.

Traders can look to buy INO off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $2.40 a share or around some more near-term support at $2.27 a share.. One can also buy INO off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a conformable percentage from your entry point.

To see more small-cap biotech stocks that could spike when they present at the conference, check out the Under-$10 Biotech Conference Plays portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.


RELATED LINKS:







Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including

CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.